AU2016378399A1 - Pharmaceutical formulations for treating kidney stones and methods for fabricating and using thereof - Google Patents

Pharmaceutical formulations for treating kidney stones and methods for fabricating and using thereof Download PDF

Info

Publication number
AU2016378399A1
AU2016378399A1 AU2016378399A AU2016378399A AU2016378399A1 AU 2016378399 A1 AU2016378399 A1 AU 2016378399A1 AU 2016378399 A AU2016378399 A AU 2016378399A AU 2016378399 A AU2016378399 A AU 2016378399A AU 2016378399 A1 AU2016378399 A1 AU 2016378399A1
Authority
AU
Australia
Prior art keywords
composition
component
stone disease
reducing agent
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016378399A
Other languages
English (en)
Inventor
Joseph BITTERMAN
Dennis Elias Saadeh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harrow IP LLC
Original Assignee
Harrow IP LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harrow IP LLC filed Critical Harrow IP LLC
Publication of AU2016378399A1 publication Critical patent/AU2016378399A1/en
Assigned to HARROW HEALTH, INC. reassignment HARROW HEALTH, INC. Alteration of Name(s) of Applicant(s) under S113 Assignors: IMPRIMIS PHARMACEUTICALS, INC.
Assigned to HARROW IP, LLC reassignment HARROW IP, LLC Request for Assignment Assignors: HARROW HEALTH, INC.
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2016378399A 2015-12-22 2016-12-19 Pharmaceutical formulations for treating kidney stones and methods for fabricating and using thereof Abandoned AU2016378399A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562271020P 2015-12-22 2015-12-22
US62/271,020 2015-12-22
US201562272894P 2015-12-30 2015-12-30
US62/272,894 2015-12-30
PCT/US2016/067466 WO2017112574A1 (en) 2015-12-22 2016-12-19 Pharmaceutical formulations for treating kidney stones and methods for fabricating and using thereof

Publications (1)

Publication Number Publication Date
AU2016378399A1 true AU2016378399A1 (en) 2018-06-28

Family

ID=59064032

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016378399A Abandoned AU2016378399A1 (en) 2015-12-22 2016-12-19 Pharmaceutical formulations for treating kidney stones and methods for fabricating and using thereof

Country Status (7)

Country Link
US (1) US20170172960A1 (enExample)
EP (1) EP3393469A4 (enExample)
JP (1) JP2019504024A (enExample)
KR (1) KR20180095647A (enExample)
AU (1) AU2016378399A1 (enExample)
CA (1) CA3009332A1 (enExample)
WO (1) WO2017112574A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12472160B2 (en) * 2017-06-16 2025-11-18 Altibio, Inc. Modified-release tiopronin compositions, kits and methods for treating cystinuria and related disorders
US20190282525A1 (en) * 2018-03-19 2019-09-19 Cronus Research Labs Private Limited Tiopronin oral composition
WO2020092402A1 (en) * 2018-10-30 2020-05-07 Harrow Health, Inc. Pharmaceutical compositions of tiopronin and methods for preparing thereof
WO2022015743A1 (en) * 2020-07-14 2022-01-20 GyanRx Sciences, Inc. Methods of treating kidney stones
WO2022250957A2 (en) * 2021-05-10 2022-12-01 Altibio, Inc. Thioester prodrugs for the treatment of renal anomalies
BE1033278B1 (fr) * 2024-12-31 2026-08-12 Renal Care & Res Composition anti-lithiase
BE1033276B1 (fr) * 2024-12-31 2026-08-12 Renal Care & Res Composition anti-lithiase
WO2026146126A1 (fr) 2024-12-31 2026-07-09 Renal Care & Research Composition anti-lithiase

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050025839A1 (en) * 2003-07-28 2005-02-03 Polli James Edward Formulation approach to enhance transporter-mediated drug uptake
CN100361653C (zh) * 2004-09-29 2008-01-16 上海华源医药科技发展有限公司 硫普罗宁软胶囊
AR052225A1 (es) * 2004-11-04 2007-03-07 Astrazeneca Ab Formulaciones de tabletas de liberacion modificada par inhibidores de la bomba de protones
CN1833637A (zh) * 2005-03-16 2006-09-20 安徽龙科马生物制药有限责任公司 一种新的硫普罗宁冻干粉制剂及其制备方法
CN1698594A (zh) * 2005-04-25 2005-11-23 中国药科大学 硫普罗宁的缓释制剂
CN101062024B (zh) * 2006-04-25 2012-11-07 刘祥华 一种硫普罗宁组合药物及其制备方法
FR2967578B1 (fr) * 2010-11-18 2012-12-28 Advicenne Pharma Composition pharmaceutique comportant des sels de citrate et de bicarbonate, et son utilisation pour le traitement de la cystinurie
US8916609B2 (en) * 2011-06-10 2014-12-23 New York University Compounds as L-cystine crystallization inhibitors and uses thereof
CN102516143B (zh) * 2012-01-06 2013-11-20 刘全胜 一种硫普罗宁无菌粉及其制剂与制备方法
WO2014145195A1 (en) * 2013-03-15 2014-09-18 Cerovene, Inc. Pharmaceuticals comprising a ph-dependent component and ph-raising agent

Also Published As

Publication number Publication date
CA3009332A1 (en) 2017-06-29
US20170172960A1 (en) 2017-06-22
WO2017112574A1 (en) 2017-06-29
EP3393469A4 (en) 2019-09-25
JP2019504024A (ja) 2019-02-14
EP3393469A1 (en) 2018-10-31
KR20180095647A (ko) 2018-08-27

Similar Documents

Publication Publication Date Title
US20170172960A1 (en) Pharmaceutical formulations for treating kidney stones and methods for fabricating and using thereof
AU2016204931B2 (en) Method of producing physiological and therapeutic levels of nitric oxide through an oral delivery system
CA2506930C (en) Dosage forms containing a proton pump inhibitor, a nsaid, and a buffer
ES2352957T3 (es) Composiciones orales para la absorción de compuestos de fósforo.
CZ2003199A3 (cs) Rychle expandující kompozice pro řízené uvolňování léčiva a retenci léčiva v žaludku a lékové formy obsahující tuto kompozici
JP2019194265A (ja) 心臓発作及び虚血損傷のハロゲン治療
US20090075950A1 (en) Dosage Forms Containing A PPI, NSAID And A Buffer
JP2017141275A (ja) ニトライトの医薬製剤及びそれらの使用
JPS62501845A (ja) 制御放出塩化カリウム
EA028749B1 (ru) Солюбилизированный капсулированный препарат 1,1-диметилэтил [(1s)-1-{[(2s,4r)-4-(7-хлор-4-метоксиизохинолин-1-илокси)-2-({(1r,2s)-1-[(циклопропилсульфонил)карбамоил]-2-этенилциклопропил}карбамоил)пирролидин-1-ил]карбонил}-2,2-диметилпропил]карбамата
JP5879359B2 (ja) クエン酸及び重炭酸塩を含んでなる医薬組成物、並びにシスチン尿症を治療するためのこれらの使用
JP5678088B2 (ja) ４−メチルピラゾール製剤
WO2018084959A2 (en) Pharmaceutical quality strontium l-lactate
WO2007021032A1 (ja) 正確な用量分割機能を有する製剤
JP2023529001A (ja) 結晶形のラベキシモドを含む経口製剤
ES2946260T3 (es) Sistemas de dos componentes que comprenden ácido acetilsalicílico y una sal de fosfato
CN116650490B (zh) 化合物mt-1207在降低尿酸方面的应用
CN115721614B (zh) 一种α-KG缓释制剂及用途
JP2024020416A (ja) 過多月経患者及び／又は過多月経を伴う婦人科疾患を有する患者における鉄欠乏性貧血の予防及び／又は治療におけるクエン酸第二鉄の使用
EP4509172A2 (en) Oral aminodihydrophthalazinedione compositions and their use the treatment of non-viral hepatitis
EP4243804B1 (en) SUBSTANCES FOR THE TREATMENT OF HYPEROURICEMIA
ES2769551T3 (es) Composición para administración oral de magnesio, combinada con una composición dirigida a tratar la diabetes tipo 2 o sus complicaciones
US20240269165A1 (en) Fine silicon particle-containing preventive or therapeutic agent for diseases
CN118766922A (zh) 乌帕替尼的口服结肠靶向制剂及其制备方法和应用
CN119302961A (zh) 一种含有化合物a的降糖药物组合物

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: HARROW HEALTH, INC.

Free format text: FORMER NAME(S): IMPRIMIS PHARMACEUTICALS, INC.

PC1 Assignment before grant (sect. 113)

Owner name: HARROW IP, LLC

Free format text: FORMER APPLICANT(S): HARROW HEALTH, INC.

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application